SCHEMBL5367572

SCHEMBL5367572

CCCS(=O)(=O)c1cc(C(=O)OC)nc(S(=O)(=O)CCC)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ALDH1A1 P00352 8/20 0.38
▸ LMNA P02545 4/20 0.38
▸ GAA P10253 2/20 0.38
▸ HPGD P15428 6/20 0.38
▸ HTT P42858 2/20 0.38
▸ S1PR4 O95977 2/20 0.38
▸ S1PR1 P21453 2/20 0.38
▸ STAT3 P40763 2/20 0.38
▸ STAT1 P42224 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MITF O75030 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ SDHB P21912 1/20 0.34
▸ MAPK1 P28482 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363392 0.89 THRB (0.37) KDM4EHPGDSDHB
SCHEMBL5366847 0.79 CNR2 (0.39) KDM4EALDH1A1MAPTMAPK1GABRP
SCHEMBL6108108 0.76 LMNA (0.47) KDM4EKMT2AALDH1A1LMNAHPGD
SCHEMBL5365540 0.73 LMNA (0.47) KDM4EKMT2AALDH1A1LMNAHPGD
SCHEMBL3854479 0.73 ALDH1A1 (0.43) KDM4EKMT2AALDH1A1LMNAGAA
SCHEMBL3857883 0.68 HCAR3 (0.38) KDM4EKMT2AALDH1A1LMNAGAA
SCHEMBL3857887 0.68 HCAR3 (0.38) KDM4EKMT2AALDH1A1LMNAGAA
SCHEMBL3856172 0.68 KDM4E (0.35) KDM4EKMT2AALDH1A1LMNAGAA
SCHEMBL20886358 0.66 GABRP (0.46) KDM4EALDH1A1GAASMN1; SMN2NPSR1
SCHEMBL20886389 0.65 MAPK1 (0.41) KDM4EALDH1A1GAASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291645-B2 Phenylalanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2007-11-06 — — US disclosed
US-7015216-B2 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2006-03-21 — — US disclosed
US-20040127486-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. 2004-07-01 — — US disclosed
US-6689781-B2 TREATING AN INFLAMMATORY CONDITION IN A MAMMALIAN PATIENT WHICH CONDITION IS MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. 2004-02-10 — — US disclosed
US-6677339-B2 S-3-(4-(3,5-DICHLOROPYRID-4-YLCARBOXAMIDO)PHENYL)-2-(4,6-DIMET HOXY-1,3,5-TRIAZIN-2-YLAMINO)PROPANOIC ACID FOR EXAMPLE; INHIBIT BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS, FOR TREATING IMMUNE OR INFLAMMATORY DISORDERS CELLTECH R & D LIMITED (GB) 2004-01-13 — — US disclosed
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-07-04 — — US disclosed
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-05-09 — — US disclosed
US-20020028812-A1 Phenylalanine derivatives CELLTECH CHIROSCIENCE LIMITED (GB) 2002-03-07 — — US disclosed
US-6348463-B1 Phenylalanine derivatives CELLTECH THERAPEUTICS LIMITED (GB) 2002-02-19 — — US disclosed
WO-2002008222-A2 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2002-01-31 — — WO disclosed
WO-2002008206-A1 3-AMINO-2-(4-AMINOCARBONYLOXY)PHENYL-PROPIONIC ACID DERIVATIVES AS ALPHA-4- INTEGRIN INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2002-01-31 — — WO disclosed
EP-1117657-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2001-07-25 — — EP disclosed
WO-2000018759-A1 PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 2000-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 KDM4E 469/4885KMT2A 2387/4885ALDH1A1 1200/4885
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors ITGAL, ITGB4, ITGA4 KDM4E 2953/4885KMT2A 2842/4885ALDH1A1 593/4885
US-20020028812-A1 Phenylalanine derivatives PAH, FPR1, VCAM1 KDM4E 1423/4885KMT2A 1645/4885ALDH1A1 330/4885
US-20040127486-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 KDM4E 469/4885KMT2A 2387/4885ALDH1A1 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback